September 1, 2003 |
Of the millions of Americans infected with hepatitis C, only half respond to treatment. The others live with the constant threat that their health may suddenly, and fatally, deteriorate. A new drug could improve those odds. When used with the antiviral drug interferon, a medication called Zadaxin may help thousands of patients better fight the disease. "This medication looks promising for people who don't respond to other drugs," says Dr.
May 14, 1995 |
The incidence of new hepatitis C infections among intravenous drug abusers has dropped unexpectedly by a dramatic 80% since 1990, according to preliminary results from the Centers for Disease Control and Prevention. Transmission of the virus among drug abusers is thought to account for as much as 85% of the hepatitis C infections discovered each year--a number that totaled 150,000 in 1990.
June 17, 1998 |
Schering-Plough Corp. said Tuesday it is seeking U.S. regulatory approval to sell its combination hepatitis C therapy to a wider group of patients, including those who haven't been treated already with standard hepatitis-fighting drugs. The news follows an announcement last month that the combination of drugs developed by Schering-Plough and Costa Mesa-based ICN Pharmaceuticals Inc. offers significant benefits to previously untreated patients.
December 10, 1998 |
Schering-Plough Corp. and ICN Pharmaceuticals Inc. won regulatory approval Wednesday to sell their combination hepatitis C treatment to a wider group of patients. The Food and Drug Administration approved the combination therapy known as Rebetron for use in patients who haven't been treated already with standard hepatitis-fighting drugs. The wider use should boost sales for Schering-Plough, the eighth biggest U.S. drug maker, and Costa Mesa-based ICN, Eastern Europe's largest drug maker.
August 17, 2001 |
ICN Pharmaceuticals Inc.'s ribavirin drug, used in combination with a Schering-Plough Corp. drug to treat hepatitis C, may face generic competition within a year if an unidentified company wins Food and Drug Administration approval for its version. The FDA's Web site said the agency has received a request from a company to sell a generic version of ribavirin, which is sold by Schering-Plough with its own hepatitis C drugs Intron A and Peg-Intron.
April 10, 2008 |
Abu Ubaida al Masri, a suspected mastermind of Al Qaeda plots including the London transportation bombings of 2005, has died of an infectious disease in Pakistan, Western anti-terrorism officials said Wednesday. The Egyptian militant is thought to have died of hepatitis C, a U.S. anti-terrorism official said.
March 21, 2014 |
U.S. lawmakers have asked Gilead Sciences Inc. to justify the price of its new $84,000 drug for hepatitis C patients amid growing concern about the high cost to taxpayers and consumers. In a letter to the Foster City, Calif., company, Rep. Henry A. Waxman (D-Beverly Hills) and two other Democratic lawmakers asked Gilead Chief Executive John C. Martin to explain the rationale for selling Sovaldi for $1,000 per pill. Medical experts say previous therapies for hepatitis C helped only about half of patients and had numerous side effects, such as flu-like symptoms, anemia and depression.
CALIFORNIA | LOCAL
July 8, 1994 |
Researchers at UCI Medical Center need 20 hepatitis C patients to participate in an 18-month study of an interferon drug. The disease must have been diagnosed at least six months ago, but patients must not have received any treatment, nurse and study coordinator Barbara Walker said. The tests will be run under the supervision of Dr. John Hoefs, director of the UCI Liver Disease Program. All treatment will be free to test patients.
May 19, 1998 |
A combination of drugs developed by Schering-Plough Corp. and Costa Mesa-based ICN Pharmaceuticals Inc. offers significant benefits in fighting hepatitis C in patients who haven't ever been treated, new studies found. The studies are significant because previously the combination of ICN's Rebetol and Schering-Plough's Intron-A proved effective for hepatitis C patients who suffered a relapse. The current results could expand use of the drugs.